We hypothesize that pathological tau's abnormal interaction with the ESCRT machinery for exosomal release is driven by site-specific loss of O-GlcNAcylation at T212, which normally prevents phosphorylation at nearby sites (S214, S262) that enhance TSG101/ESCRT-I binding. In normal states, O-GlcNAcylation at T212 competes with these pro-aggregation phosphorylations, limiting tau's engagement with ESCRT components and preventing pathological secretion. In disease states, reduced O-GlcNAcytransfera
Target unique glycosylation patterns on tau-containing vesicles using synthetic lectins or glycan-binding proteins. Pathological tau trafficking may alter vesicle surface glycoproteins, creating distinctive molecular signatures absent in normal vesicles.
Debate provenance: derived from debate `sess_SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd` on question: The debate identified fundamental druggability challenges for these targets due to their essential roles, but specific molecular appro
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
GlycanProteostasis Stress Response
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
4/11
dimensions won
O-GlcNAcylation at T212 competes with ph
1/11
dimensions won
Vesicle Surface Glycan Pattern Recogniti
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.72
0.60
Evidence
0.65
0.55
Novelty
0.78
0.60
Feasibility
0.72
0.00
Impact
0.00
0.00
Druggability
0.00
0.00
Safety
0.00
0.00
Competition
0.00
0.00
Data
0.00
0.00
Reproducible
0.00
0.00
KG Connect
0.12
0.24
Score Breakdown
Dimension
O-GlcNAcylation at T212 compet
Vesicle Surface Glycan Pattern
Mechanistic
0.720
0.600
Evidence
0.650
0.550
Novelty
0.780
0.600
Feasibility
0.720
0.000
Impact
0.000
0.000
Druggability
0.000
0.000
Safety
0.000
0.000
Competition
0.000
0.000
Data
0.000
0.000
Reproducible
0.000
0.000
KG Connect
0.118
0.235
Evidence
O-GlcNAcylation at T212 competes with phosphorylation to red
No evidence citations yet
Vesicle Surface Glycan Pattern Recognition
No evidence citations yet
Debate Excerpts
O-GlcNAcylation at T212 competes with phosphorylat
4 rounds · quality: 0.95
Persona-Theorist
Based on the knowledge gap regarding selective targeting of tau-containing vesicles, here are 7 novel therapeutic hypotheses:
## Hypothesis 1: Tau Conformational State-Specific Nanobody Targeting
**D...
Persona-Skeptic
I'll provide a rigorous critique of each hypothesis, identifying weaknesses and gaps in the evidence. Let me analyze these systematically:
## Hypothesis 1: Tau Conformational State-Specific Nanobody ...
```json
{
"ranked_hypotheses": [
{
"title": "Autophagosome Marker Hijacking Strategy",
"description": "Design therapeutics that mimic or enhance LC3-tau interactions to redirect tau-...
Vesicle Surface Glycan Pattern Recognition
4 rounds · quality: 0.95
Persona-Theorist
Based on the knowledge gap regarding selective targeting of tau-containing vesicles, here are 7 novel therapeutic hypotheses:
## Hypothesis 1: Tau Conformational State-Specific Nanobody Targeting
**D...
Persona-Skeptic
I'll provide a rigorous critique of each hypothesis, identifying weaknesses and gaps in the evidence. Let me analyze these systematically:
## Hypothesis 1: Tau Conformational State-Specific Nanobody ...